Spurious elevation of serum PSA after curative treatment for prostate cancer: Clinical consequences and the role of heterophilic antibodies

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 2, 2012, Pages 182-188

  Anderson, C B ^a   Pyle, A L ^a   Woodworth, A ^a   Cookson, M S ^a   Smith Jr , J A ^a   Barocas, D A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

heterophile antibody; prostate specific antigen; PSA; surveillance

Indexed keywords

HETEROPHILE ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ANTIBODY BLOOD LEVEL; ANTIGEN DETECTION; ANTIGEN STRUCTURE; ANTIGENICITY; ARTICLE; CANCER RISK; CLINICAL EVALUATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

AGED; ANTIBODIES, HETEROPHILE; FALSE POSITIVE REACTIONS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84861234414     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.58     Document Type: Article

References (31)

1. Loeb S, Schaeffer EM, Chan DW, Carter HB,Walsh PC, Sokoll LJ. Investigation of human anti-mouse antibodies as potential cause of postprostatectomy PSA elevation. Urology 2009; 73: 947-949
2. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008; 54: E11-E79
3. Henry N, Sebe P, Cussenot O. Inappropriate treatment of prostate cancer caused by heterophilic antibody interference. Nat Clin Pract Urol 2009; 6: 164-167
4. Fritz BE, Hauke RJ, Stickle DF. New onset of heterophilic antibody interference in prostate-specific antigen measurement occurring during the period of post-prostatectomy prostatespecific antigen monitoring. Ann Clin Biochem 2009; 46 (Pt 3): 253-256
5. Park S, Wians Jr FH, Cadeddu JA. Spurious prostate-specific antigen (PSA) recurrence after radical prostatectomy: interference by human antimouse heterophile antibodies. Int J Urol 2007; 14: 251-253
6. Morgan BR, Tarter TH. Serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer. J Urol 2001; 166: 2311-2312
7. Camacho T, Mora J, Segura A, Guitian J, Lema F, Bandin J et al. Falsely increased prostate-specific antigen concentration attributed to heterophilic antibodies. Ann Clin Biochem 2002; 39 (Pt 2): 160-161
8. McAuley I, Steinhoff G, McNeely M, Blood P. Incorrect biochemistry complicates prostate cancer management. Can J Urol 2002; 9: 1496-1497
9. Kummar S, Shafi NQ. False elevations in prostate-specific antigen levels affecting patient management. Clin Adv Hematol Oncol 2004; 2: 599-601; discussion 2
10. Warren DJ, Bjerner J, Paus E, Bormer OP, Nustad K. Use of an in vivo biotinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies. Clin Chem 2005; 51: 830-838
11. Boscato LM, Stuart MC. Heterophilic antibodies: a problem for all immunoassays. Clin Chem 1988; 34: 27-33
12. Cantor D. Reason for limitations of heterophilic blocking tube use on certain beckman coulter access assays. Clin Chem 2005; 51: 1311
13. Bertholf RL, Johannsen L, Guy B. False elevation of serum CA- 125 level caused by human anti-mouse antibodies. Ann Clin Lab Sci 2002; 32: 414-418
14. Sapin R, Simon C. False hyperprolactinemia corrected by the use of heterophilic antibody-blocking agent. Clin Chem 2001; 47: 2184-2185
15. Pathologists CoA. K-18 General Ligand Assay Participant Summary. General Ligand Assay Proficiency Testing 2011
16. Kaplan LA, Pesce AJ. Clinical Chemistry: Theory, Analysis, and Correlation. 3rd ed. Mosby: St Louis, 1996
17. Boscato LM, Stuart MC. Heterophilic antibodies: a problem for all immunoassays. Clin Chem 1988; 34: 27-33
18. Preissner CM, Dodge LA, O'Kane DJ, Singh RJ, Grebe SK. Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays. Clin Chem 2005; 51: 208-210
19. Ismail Y, Ismail AA. Erroneous laboratory results: what clinicians need to know. Clin Med 2007; 7: 357-361
20. Bjerner J, Nustad K, Norum LF, Olsen KH, Bormer OP. Immunometric assay interference: incidence and prevention. Clin Chem 2002; 48: 613-621
21. Boerman OC, Segers MF, Poels LG, Kenemans P, Thomas CM. Heterophilic antibodies in human sera causing falsely increased results in the CA 125 immunofluorometric assay. Clin Chem 1990; 36: 888-891
22. Levin O, Morris LF, Wah DT, Butch AW, Yeh MW. Falsely elevated plasma parathyroid hormone level mimicking tertiary hyperparathyroidism. Endocr Pract 2011; 17: e8-11
23. Ross HA, Menheere PP, Thomas CM, Mudde AH, Kouwenberg M, Wolffenbuttel BH. Interference from heterophilic antibodies in seven current TSH assays. Ann Clin Biochem 2008; 45 (Pt 6): 616
24. Spencer DV, Nolte FS, Zhu Y. Heterophilic antibody interference causing false-positive rapid human immunodeficiency virus antibody testing. Clin Chim Acta 2009; 399: 121-122
25. Butler SA, Cole LA. Use of heterophilic antibody blocking agent (HBT) in reducing false-positive hCG results. Clin Chem 2001; 47: 1332-1333
26. Zhu Y, Jenkins MM, Brass DA, Ravago PG, Horne BD, Dean SB et al. Heterophilic antibody interference in an ultra-sensitive 3-site sandwich troponin I immunoassay. Clin Chim Acta 2008; 395: 181-182
27. Hunter WM, Budd PS. Circulating antibodies to ovine and bovine immunoglobulin in healthy subjects: a hazard for immunoassays. Lancet 1980; 2: 1136
28. Leibowitz SB, Oh WK. Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen results. J Urol 2003; 170 (4 Pt 1): 1305
29. Bjerner J, Bormer OP, Nustad K. The war on heterophilic antibody interference. Clin Chem 2005; 51: 9-11
30. Soletormos G, Semjonow A, Sibley PE, Lamerz R, Petersen PH, Albrecht W et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 2005; 51: 1342-1351
31. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177: 540-545